FDA Accepts Cytokinetics' Application for Cardiovascular Drug

Zacks12-04

Cytokinetics, Incorporated CYTK announced that the FDA has accepted the company’s new drug application (NDA) for lead pipeline candidate, aficamten. Aficamten is a next-in-class cardiac myosin ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2488097839?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/vZlajmbYZzKfSC9h66RaJg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ae98f9f4477af1de31a0a61cde692d41","is_english":true,"pubTime":"2024-12-04 02:37","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2488097839","market":"us","top_or_hot":-1,"title":"FDA Accepts Cytokinetics' Application for Cardiovascular Drug","media":"Zacks","content":"<div>\n<p>Cytokinetics, Incorporated CYTK announced that the FDA has accepted the company’s new drug application (NDA) for lead pipeline candidate, aficamten.\nAficamten is a next-in-class cardiac myosin ...</p>\n\n<a href=\"https://finance.yahoo.com/news/fda-accepts-cytokinetics-application-cardiovascular-183700233.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Accepts Cytokinetics' Application for Cardiovascular Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Accepts Cytokinetics' Application for Cardiovascular Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-04 02:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/fda-accepts-cytokinetics-application-cardiovascular-183700233.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cytokinetics, Incorporated CYTK announced that the FDA has accepted the company’s new drug application (NDA) for lead pipeline candidate, aficamten.\nAficamten is a next-in-class cardiac myosin ...</p>\n\n<a href=\"https://finance.yahoo.com/news/fda-accepts-cytokinetics-application-cardiovascular-183700233.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://finance.yahoo.com/news/fda-accepts-cytokinetics-application-cardiovascular-183700233.html","article_id":"2488097839","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/vZlajmbYZzKfSC9h66RaJg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ae98f9f4477af1de31a0a61cde692d41"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2488097839","pubTimestamp":1733251020,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Cytokinetics, Incorporated CYTK announced that the FDA has accepted the company’s new drug application  for lead pipeline candidate, aficamten.Aficamten is a next-in-class cardiac myosin inhibitor. The NDA is seeking approval of the candidate for the treatment of obstructive hypertrophic cardiomyopathy .Year to date, Cytokinetics’ shares have lost 39.5% compared with the industry’s 7% decline.The NDA is supported by the results from the phase III SEQUOIA-HCM  study on aficamten in patients with symptomatic obstructive HCM.Results from SEQUOIA-HCM showed that treatment with aficamten for 24 weeks significantly improved exercise capacity compared to placebo, increasing peak oxygen uptake measured by cardiopulmonary exercise testing by 1.8 ml/kg/min compared to baseline in patients treated with aficamten versus 0.0 ml/kg/min in patients treated with placebo.Meanwhile, Bayer AG BAYRY will acquire rights to aficamten in Japan. As per the joint development plan, Bayer plans to conduct a phas","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4531":"中概回港概念","BK4505":"高瓴资本持仓","BK4585":"ETF&股票定投概念","CSTL":"Castle Biosciences, Inc.","BK4007":"制药","BK4588":"碎股","BK4082":"医疗保健设备","CSII":"Cardiovascular Systems","HCM":"和黄医药","BK4196":"保健护理服务","BAYRY":"Bayer A.G.","SPRO":"Spero Therapeutics Inc.","CYTK":"Cytokinetics"},"translate_title":"FDA接受Cytokinetics心血管药物申请","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BAYRY":1,"CSII":1,"CSTL":1,"CYTK":1,"HCM":1,"SPRO":1},"content_text":"Cytokinetics, Incorporated CYTK announced that the FDA has accepted the company’s new drug application (NDA) for lead pipeline candidate, aficamten.\nAficamten is a next-in-class cardiac myosin inhibitor. The NDA is seeking approval of the candidate for the treatment of obstructive hypertrophic cardiomyopathy (HCM).\nYear to date, Cytokinetics’ shares have lost 39.5% compared with the industry’s 7% decline.\nImage Source: Zacks Investment Research\nCYTK’s NDA Acceptance\nThe regulatory body assigned a standard review to the NDA and set a target action date of Sept. 26, 2025.\nThe FDA also informed the company that it is not planning to hold an advisory committee meeting to discuss the application.\nThe NDA is supported by the results from the phase III SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM) study on aficamten in patients with symptomatic obstructive HCM.\nResults from SEQUOIA-HCM showed that treatment with aficamten for 24 weeks significantly improved exercise capacity compared to placebo, increasing peak oxygen uptake measured by cardiopulmonary exercise testing by 1.8 ml/kg/min compared to baseline in patients treated with aficamten versus 0.0 ml/kg/min in patients treated with placebo.\nStatistically significant improvements were observed in all 10 prespecified secondary endpoints. Treatment-emergent serious adverse events occurred in 5.6% and 9.3% of patients on aficamten and placebo, respectively. Core echocardiographic left ventricular ejection fraction (LVEF) was less than 50% in five patients on aficamten compared to one on placebo. There were no instances of worsening heart failure or treatment interruptions due to low LVEF.\nAdditional analyses from SEQUOIA-HCM have demonstrated that treatment with aficamten is associated with favorable cardiac remodeling as well as improvements in cardiac structure, function and biomarkers without negatively impacting systolic function.\nWe remind investors that the FDA had granted orphan drug designation to aficamten for the treatment of symptomatic HCM in January 2021. It also granted Breakthrough Therapy Designation in December 2021 for treating obstructive HCM.\nA potential approval and the successful development of the candidate will be a significant boost for late-stage, specialty cardiovascular biopharmaceutical company, CYTK, as it currently does not have any approved product in its portfolio.\nCYTK’s Pipeline Progress\nAficamten is also currently being evaluated in MAPLE-HCM, a phase III clinical trial assessing aficamten as monotherapy compared to metoprolol as monotherapy in patients with obstructive HCM. FOREST-HCM is an open-label extension clinical study of aficamten in patients with HCM.\nMeanwhile, Bayer AG BAYRY will acquire rights to aficamten in Japan. As per the joint development plan, Bayer plans to conduct a phase III study in Japanese patients with obstructive HCM. On the other hand, Cytokinetics will expand ACACIA-HCM, the ongoing global late-stage study of aficamten in patients with non-obstructive HCM, into Japan. This study is intended to support the potential marketing authorization of aficamten in Japan for Bayer. CYTK will also expand CEDAR-HCM, its ongoing study for pediatric patients with obstructive HCM.\nPer the financial terms of the agreement, Cytokinetics will receive an upfront payment of €50 million and an additional €90 million upon achieving milestones through commercial launch, including €20 million, which are near-term. In addition, Cytokinetics is eligible to receive up to €490 million in commercial milestone payments upon achieving certain sales milestones by Bayer and tiered royalties on net sales of aficamten in Japan.\nZacks Rank and Stocks to Consider\nCytokinetics currently carries a Zacks Rank #3 (Hold).\nA couple of better-ranked stocks in the biotech sector are Spero Therapeutics SPRO and Castle Biosciences, Inc. CSTL, both carrying a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.\nIn the past 60 days, estimates for Spero Therapeutics’ 2024 loss per share have narrowed from $1.59 to $1.13. Estimates for 2025 loss per share have narrowed from $1.54 to 54 cents.\nSpero Therapeutics’ earnings beat estimates in two of the trailing four quarters and missed the mark on the other two occasions, delivering an average surprise of 94.42%.\nIn the past 60 days, estimates for Castle Biosciences’ 2024 loss per share have narrowed from 58 cents to 8 cents. Loss per share estimates for 2025 have narrowed from $2.13 to $1.88 during the same time frame. Year to date, shares of CSTL have surged 44.6%.\nCSTL’s earnings beat estimates in each of the trailing four quarters, the average surprise being 172.72%. \nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nBayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report\nCytokinetics, Incorporated (CYTK) : Free Stock Analysis Report\nSpero Therapeutics, Inc. (SPRO) : Free Stock Analysis Report\nCastle Biosciences, Inc. (CSTL) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2488097839"}